Dr. Sanjay Mehta, MD, FRCPC, FCCP

Mehta

Rank / Affiliations

  • Professor of Medicine
  • Lawson Health Research Institute, Scientist
  • Director, Southwestern Ontario Pulmonary Hypertension Program
  • Founding Board Member, Board of Directors, and Eternal PHriend, PHA (Pulmonary Hypertension Association) of Canada

Training

  • Undergraduate, BSc (Hons) Biochemistry, McGill University 1984
  • MDCM, McGill University 1988
  • Residency, Internal Medicine, McGill University 1988-1991
  • Fellowship, Respirology, McGill University 1991-1993
  • Fellowship, Respiratory Research, McGill University 1992-1994
  • Fellowship, Respiratory Research, Harvard University 1994-1996

Clinical Interest

  • Pulmonary hypertension, pulmonary thromboembolic disease
  • Pulmonary and exercise physiology

Research Interest

Current Research Projects in Sepsis / Acute Lung Injury 

  • Mechanisms of septic pulmonary microvascular endothelial cell injury
  • Mechanisms of septic murine and human pulmonary microvascular endothelial cell apoptosis
  • Mechanism of the protective effect of alveolar epithelial cells in septic pulmonary microvascular endothelial cell injury
  • A novel bioassay to predict clinical outcomes in human patients with sepsis

Current Research Projects in Pulmonary Hypertension

  • Physiologic and hemodynamic correlates of 6-minute walk distance in scleroderma-associated pulmonary artery hypertension
  • Role of brain natriuretic peptide (BNP) monitoring during exercise in pulmonary artery hypertension
  • Incidence and clinical correlates of chronic thromboembolic pulmonary hypertension post pulmonary embolism
  • Clinical Importance and Treatment of COPD-Associated Pulmonary Hypertension

Research Funding

  • Heart & Stroke Foundation of Ontario/Canada
  • Ontario Ministry of Health AMOSO Innovation Fund
  • Ontario Thoracic Society / Ontario Lung Association
  • Lawson Health Research Institute
  • Department of Medicine Program in Experimental Medicine (POEM)

Awards (past 5 years)

Teaching Awards

  • 2014 - Western University Internal Medicine Residency Training Program Mentorship Award; nominated by Dr Anurag Bhalla
  • 2017 - Western University Internal Medicine Residency Training Program Mentorship Award; nominated by Dr Nikesh Adunuri

Clinical Awards

  • 2013 - Outstanding Canadian Pulmonary Hypertension Medical / Health Professional Award, Pulmonary Hypertension Association (PHA) of Canada

Research Awards

  • 2014                Outstanding Research Award, Program in Experimental Medicine, Department of Medicine, London Health Sciences Centre, Schulich School of Medicine, Faculty of Medicine and Dentistry, Western Univ ($15,000)
  • 2014                POEM Research Scientist Recognition, Program in Experimental Medicine, Department of Medicine, London Health Sciences Centre, Schulich School of Medicine, Faculty of Medicine and Dentistry, UWO ($20,000)
  • 2015                Outstanding Research Award, Program in Experimental Medicine, Department of Medicine, London Health Sciences Centre, Schulich School of Medicine, Faculty of Medicine and Dentistry, Western Univ ($10,000)
  • 2015                POEM Research Scientist Recognition, Program in Experimental Medicine, Department of Medicine, London Health Sciences Centre, Schulich School of Medicine, Faculty of Medicine and Dentistry, UWO ($20,000)
  • 2016                1st place, Poster Session 4 (New Drugs in Development / Study Endpoints in PH), Pulmonary Hypertension Global Science Forum, June 3-4, 2016, Berlin, Germany: M Mehta and S Mehta (presenter). “Should Effective PAH-Targeted Drug Therapy bet Withdrawn as per Ontario Drug Benefit’s Cost-saving Strategy?”
  • 2017                POEM Research Scientist Recognition, Program in Experimental Medicine, Department of Medicine, London Health Sciences Centre, Schulich School of Medicine, Faculty of Medicine and Dentistry, UWO ($20,000)
  • 2018                POEM Research Scientist Recognition, Program in Experimental Medicine, Department of Medicine, London Health Sciences Centre, Schulich School of Medicine, Faculty of Medicine and Dentistry, UWO ($20,000)

     

Research Awards to Supervised Students

  • 2014 - Valerie Arpino, BSc, Lawson Health Research Institute Internal Research Fund Studentship, $15,000 - "Endothelial dysfunction/injury in murine sepsis is regulated by TIMP3"
  • 2015 - Valerie Arpino, BSc, Lawson Health Research Institute London Research Day, Top Poster - Cardio-Respiratory-Physiology Section - "Endothelial dysfunction/injury in murine sepsis is regulated by TIMP3"
  • 2016 - Sylvia Rinaldi, MSc, Paroian Family PHA Canada Research Scholarship - "Nutritional indicators and metabolic state of patients with pulmonary hypertension"
  • 2014 - Valerie Arpino, BSc, Lawson Health Research Institute Internal Research Fund Studentship, $15,000 - "Endothelial dysfunction/injury in murine sepsis is regulated by TIMP3"
  • 2015 - Valerie Arpino, BSc, Lawson Health Research Institute London Research Day, Top Poster - Cardio-Respiratory-Physiology Section - "Endothelial dysfunction/injury in murine sepsis is regulated by TIMP3"
  • 2016 - Sylvia Rinaldi, MSc, Paroian Family PHA Canada Research Scholarship, $10,000 - "Nutritional indicators and metabolic state of patients with pulmonary hypertension"
  • 2016 - Marcello Masciantonio, BSc, Lawson Health Research Institute Internal Research Fund Studentship, $15,000. “Septic microvascular barrier dysfunction is modulated by tissue inhibitors of metalloproteinases”
  • 2017 - Marcello Masciantonio, BSc, 2nd Place Honourable Mention, Basic Science Category, Canadian Thoracic Society Research Poster Competition, May 2017, Washington, DC. “Septic microvascular barrier dysfunction is modulated by tissue inhibitors of metalloproteinases”
  • 2017 - Marcello Masciantonio, BSc, Outstanding Research Poster Scholarship Award, $1000, American Thoracic Society, ATS International Conference, May 2017, Washington, DC. “Septic microvascular barrier dysfunction is modulated by tissue inhibitors of metalloproteinases”
  • 2017 - Sylvia Rinaldi, MSc, Paroian Family PHA Canada Research Scholarship, $10,000. “Long term effect of changes in Nutritional indicators and metabolic state on patients with pulmonary hypertension”
  • 2017 - Devika Jayawardena, MSc, Lawson Health Research Institute Internal Research Fund Studentship, $15,000. “Septic microvascular barrier dysfunction is modulated by tissue inhibitors of metalloproteinases”

Selected Publications (past 5 years)

2014

2015

  • Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. Effect of Macitentan on Hospitalizations: Results from the Seraphin Trial. Journal of the American College of Cardiology: Heart Failure 2015 Jan;3(1):1-8. doi: 10.1016/j.jchf.2014.07.013. PMID: 25457902. Impact Factor 2.0
  • Huang, J, Mehta S, Mura M. Decline in 6-min walk distance predicts clinical progression in pulmonary arterial hypertension. Respiration 2015;89:365-373. doi:10.1159/000370124. PMID: 25791910. Impact Factor 2.9
  • Gill SE, Rohan M, and Mehta S. Role of pulmonary microvascular endothelial cell apoptosis in murine sepsis-induced lung injury in vivo. Respiratory Research 2015 Sep 16 (9);16(1):109. doi: 10.1186/s12931-015-0266-7. PMID: 26376777. Impact Factor 3.64
  • Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Souza R, Torbicki A, Rubin LJ.   Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal 2015;46(6):1711-20. PMID: 26493786. Impact Factor 6.36
  • Mehta S. Caring for Pulmonary Hypertension. Pulmonary Hypertension Connections 2015;6(2):2.
  • Mehta S. Prendre Soins de l’Hypertension Pulmonaire. Liaison d’Hypertension Pulmonaire 2015;6(2):2.

2016

  • Hambly N, Alawfi F, Mehta S. Pulmonary hypertension: diagnostic approach and optimal management. Canadian Medical Association Journal 2016 Aug 9;188(11):804-12. doi: 10.1503/cmaj.151075. 2016 Aug 9;188(11):804-12. PMID: 27141034. Impact Factor 5.96
  • Arpino V, Mehta S, Wang LF, Bird R, Rohan M, Pape C, and Gill SE. Tissue inhibitor of metalloproteinases 3-dependent microvascular endothelial cell barrier function is disrupted under septic conditions. American Journal of Physiology: Heart and Circulatory Physiology 2016 Jun 1;310(11):H1455-67. doi: 10.1152/ajpheart.00796.2015. PMID: 26993226. Impact Factor 3.84
  •  Mehta S. Pulmonary Hypertension: The Winds of Change. Pulmonary Hypertension Connections 2016;7(1):2.
  •  Mehta S. L’Hypertension Pulmonaire: Le vent ca change. Liaison d’Hypertension Pulmonaire 2016;7(1):2.
  •  Mehta S, Vachiery JL. Pulmonary hypertension: The importance of correctly diagnosing the cause. European Respiratory Review 2016 Dec 25;142:372-380. doi: 10.1183/16000617.0104-2016. PMID: 27903659
  •  Mehta S. Treatment of Pulmonary Hypertension: Have we already done enough? Pulmonary Hypertension Connections 2016;7(2):4.
  •  Mehta S. L’Hypertension Pulmonaire: Est-ce que c’est fait le Traitement de l’Hypertension Pulmonaire? Liaison d’Hypertension Pulmonaire 2016;7(2):4.

2017

  • Wang LF, Mehta S, Masciantonio M, and Gill SE. Inhibition of Murine Pulmonary Microvascular Endothelial Cell Apoptosis Promotes Recovery of Barrier Function Under Septic Conditions. Mediators of Inflammation 2017;Jan 30. Article ID 3415380. https://doi.org/10.1155/2017/3415380.  
  • Mehta S, Sastry BKS, Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Hunsche E, Jansa P, Perchenet L, Pulido T, Rubin LJ, Torbicki A, Wlodarczyk J, Simonneau G, Sitbon O. Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: Results from the randomized controlled SERAPHIN trial. Chest 2017; 151(1):106-118. Impact factor 7.1  
  • Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic sub-study: The effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal 2017;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025. PMID: 28329315. Impact factor 20.2  
  • Masciantonio MG, Lee CKS, Arpino V, Mehta S, Gill SE.  ­The Balance between Metalloproteinases and TIMPs: Critical Regulator of Microvascular Endothelial Cell Function in Health and Disease. Progress in Molecular Biology and Translational Science 2017;147:101-131. http://dx.doi.org/10.1016/bs.pmbts.2017.01.001 PMID: 28413026 
  • Mehta S. How do we Choose the Optimal Treatment for Each PAH patient? Pulmonary Hypertension Connections 2017;8(1):4.  
  • Mehta S. L’Hypertension Pulmonaire: Comment Choisir le Traitement Optimal pour Chaque Patient Atteint de l’Hypertension Arterielle Pulmonaire? Liaison d’Hypertension Pulmonaire 2017;8(1):4.  
  • Mehta S. Tragedies and Advances in Pulmonary Hypertension. Pulmonary Hypertension Connections 2017;8(2):4.  
  • Mehta S. Tragedies et Percees dans l’Hypertension Pulmonaire. Liaison d’Hypertension Pulmonaire 2017;8(2):4.  
  • Kapasi A, Mehta S. Changing face of pulmonary arterial hypertension in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 2017;1(4):242-252. DOI: 10.1080/24745332.2017.1379366 2018 

2018

  • McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani H-A, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij V, Rubin LJ, Galiè N. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. Journal of the American College of Cardiology 2018 Feb;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010. PMID: 29447737. Impact factor 19.9  
  • Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, LeBrun F-O, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: data from the randomized SERAPHIN trial. PLoS One 2018 March;13(3):e0193226. doi: 10.1371/journal.pone.0193226. PMID: 29590122. Impact factor 2.8  
  • Mehta S. Living with Pulmonary Hypertension: The Beauty of Today. Pulmonary Hypertension Connections 2018;9(1):4.  
  • Mehta S. Vivre avec l’Hypertension Pulmonaire. La Beaute de notre epoque. Liaison d’Hypertension Pulmonaire 2018;9(1):4.  
  • Wang LF, Mehta S, Ahmed Y, Wallace S, Pape MC, Gill SE. Differential Mechanisms of Septic Human Pulmonary Microvascular Endothelial Cell Barrier Dysfunction Depending on the Presence of Neutrophils. Frontiers in Immunology 2018 Sep;9:1743. doi: 10.3389/fimmu.2018.01743. Impact Factor 6.4
  • Mehta S. Contributing to Pulmonary Hypertension Association of Canada – Bigger than any Single Individual. Pulmonary Hypertension Connections 2018;9(2):4.  
  • Mehta S. Contribuant a l’Association d’Hypertension Pulmonaire du Canada – Plus Grande qu’un Seul Individu. Liaison d’Hypertension Pulmonaire 2018;9(2):4.  
  • Mehta S. A Physician’s Perspectives on the Future of PH. Pulmonary Hypertension Connections 2018;9(2):28-29.  
  • Mehta S. Perspectives d’un Medecin sur le Futur de l’Hypertension Pulmonaire. Liaison d’Hypertension Pulmonaire 2018;9(2):28-29.  
  • Mehta S, Gill SE. Improving Clinical Outcomes in Sepsis and Multiple Organ Dysfunction through Precision Medicine. Journal of Thoracic Disease 2018;Nov 12. http://dx.doi.org/10.21037/jtd.2018.11.74 Impact Factor 2.4
  • Mcgoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, Mehta S, Murakami N, Wong BA. 2018 World Pulmonary Hypertension Symposium: The Importance of Patients’ Perspectives. European Respiratory Journal 2018 Dec. pii: 1801919. doi: 10.1183/13993003.01919-2018. Impact Factor 12.2

Links

www.phacanada.ca

Contact Information

London Health Sciences Centre - Victoria Hospital

Phone: (519) 667-6723

Administrative Assistant: Mary Leckie

Personal Interests

  • Running
  • Enjoying red wine with friends
  • Traveling the world